You are here
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the middle east
Bassem I. Yamout, Maya M. Zeineddine, Hani Tamim, Samia J. Khoury
Journal of Neuroimmunology, Volume 289, 15 December 2015, Pages 93–97
- Fingolimod is an oral agent with proven efficacy and safety in multiple sclerosis.
- Our cohort of 122 patients confirms its effectiveness in a real world setting.
- The most common adverse events were lymphopenia, increase liver enzymes, urinary tract infections and fatigue.
Few published studies addressed real-world clinical experience with fingolimod especially in the Middle East region.
To review our clinical experience with fingolimod at a specialized academic MS center in Lebanon.
All patients treated with fingolimod at the MS Center between October 2011 and January 2015 were retrospectively identified.
A total of 122 patients were included. The first dose observation was uneventful in 98.8% of patients. Annualized relapse rate decreased from 1.16 pre-treatment to 0.29 post-treatment representing a relative risk reduction of 75% (p < 0.0001). The proportion of patients with no new T2 or enhancing lesions was 66.3%. Seventy-six (62.3%) patients experienced adverse events with lymphopenia, increase liver enzymes, urinary tract infections and fatigue being the most common.
Our cohort confirms the effectiveness and safety of fingolimod in a real world setting